Loading…

Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications

[Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applicat...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2024-08, Vol.211, p.115347, Article 115347
Main Authors: Capella-Monsonís, Héctor, Crum, Raphael J., Hussey, George S., Badylak, Stephen F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3
container_end_page
container_issue
container_start_page 115347
container_title Advanced drug delivery reviews
container_volume 211
creator Capella-Monsonís, Héctor
Crum, Raphael J.
Hussey, George S.
Badylak, Stephen F.
description [Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.
doi_str_mv 10.1016/j.addr.2024.115347
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3065984523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X24001698</els_id><sourcerecordid>3065984523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</originalsourceid><addsrcrecordid>eNp9kMtq3DAUQEVoSSaPH8iiaNlFPdXDsmXoJgxJWkjoJoHshCxdJRo08lSyB7rtl1eO0y6z0gWde-AehC4pWVNCm6_btbY2rRlh9ZpSwev2CK2obFklWVd_QKsCdVVNuqcTdJrzlhDK2oYcoxMuZV0TIlboz5U96Gggf8HmRYcA8XmedbTYTeOUAFufwIx-iBn7iMcXwCb46I0OeEw65qDnTzw4fL25x70fdnqE5HXI2A0JJ3iGCKlAB8A7sN74CFjv96EoXrXn6KMrNFy8vWfo8eb6YfO9uvt5-2NzdVcZxtuxaohwxonOyM4wSTQDwXraGSIAetZqwTtueqqbRjRSNs5JLixnNeNSgJSWn6HPi3efhl8T5FHtfDYQgo4wTFlx0ohO1oLxgrIFNWnIOYFT--R3Ov1WlKi5vdqqub2a26ulfVn69Oaf-nLo_5V_sQvwbQGgXHnwkFQ2Hkr8JbGyg3_P_xey25bb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3065984523</pqid></control><display><type>article</type><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><source>ScienceDirect Freedom Collection</source><creator>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</creator><creatorcontrib>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</creatorcontrib><description>[Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</description><identifier>ISSN: 0169-409X</identifier><identifier>ISSN: 1872-8294</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2024.115347</identifier><identifier>PMID: 38844005</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Advancing ECM-based therapies ; ECM scaffolds ; Regenerative medicine ; Translational development ; Translational science</subject><ispartof>Advanced drug delivery reviews, 2024-08, Vol.211, p.115347, Article 115347</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38844005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capella-Monsonís, Héctor</creatorcontrib><creatorcontrib>Crum, Raphael J.</creatorcontrib><creatorcontrib>Hussey, George S.</creatorcontrib><creatorcontrib>Badylak, Stephen F.</creatorcontrib><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>[Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</description><subject>Advancing ECM-based therapies</subject><subject>ECM scaffolds</subject><subject>Regenerative medicine</subject><subject>Translational development</subject><subject>Translational science</subject><issn>0169-409X</issn><issn>1872-8294</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtq3DAUQEVoSSaPH8iiaNlFPdXDsmXoJgxJWkjoJoHshCxdJRo08lSyB7rtl1eO0y6z0gWde-AehC4pWVNCm6_btbY2rRlh9ZpSwev2CK2obFklWVd_QKsCdVVNuqcTdJrzlhDK2oYcoxMuZV0TIlboz5U96Gggf8HmRYcA8XmedbTYTeOUAFufwIx-iBn7iMcXwCb46I0OeEw65qDnTzw4fL25x70fdnqE5HXI2A0JJ3iGCKlAB8A7sN74CFjv96EoXrXn6KMrNFy8vWfo8eb6YfO9uvt5-2NzdVcZxtuxaohwxonOyM4wSTQDwXraGSIAetZqwTtueqqbRjRSNs5JLixnNeNSgJSWn6HPi3efhl8T5FHtfDYQgo4wTFlx0ohO1oLxgrIFNWnIOYFT--R3Ov1WlKi5vdqqub2a26ulfVn69Oaf-nLo_5V_sQvwbQGgXHnwkFQ2Hkr8JbGyg3_P_xey25bb</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Capella-Monsonís, Héctor</creator><creator>Crum, Raphael J.</creator><creator>Hussey, George S.</creator><creator>Badylak, Stephen F.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><author>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Advancing ECM-based therapies</topic><topic>ECM scaffolds</topic><topic>Regenerative medicine</topic><topic>Translational development</topic><topic>Translational science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capella-Monsonís, Héctor</creatorcontrib><creatorcontrib>Crum, Raphael J.</creatorcontrib><creatorcontrib>Hussey, George S.</creatorcontrib><creatorcontrib>Badylak, Stephen F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capella-Monsonís, Héctor</au><au>Crum, Raphael J.</au><au>Hussey, George S.</au><au>Badylak, Stephen F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>211</volume><spage>115347</spage><pages>115347-</pages><artnum>115347</artnum><issn>0169-409X</issn><issn>1872-8294</issn><eissn>1872-8294</eissn><abstract>[Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38844005</pmid><doi>10.1016/j.addr.2024.115347</doi></addata></record>
fulltext fulltext
identifier ISSN: 0169-409X
ispartof Advanced drug delivery reviews, 2024-08, Vol.211, p.115347, Article 115347
issn 0169-409X
1872-8294
1872-8294
language eng
recordid cdi_proquest_miscellaneous_3065984523
source ScienceDirect Freedom Collection
subjects Advancing ECM-based therapies
ECM scaffolds
Regenerative medicine
Translational development
Translational science
title Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances,%20challenges,%20and%20future%20directions%20in%20the%20clinical%20translation%20of%20ECM%20biomaterials%20for%20regenerative%20medicine%20applications&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Capella-Monson%C3%ADs,%20H%C3%A9ctor&rft.date=2024-08-01&rft.volume=211&rft.spage=115347&rft.pages=115347-&rft.artnum=115347&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2024.115347&rft_dat=%3Cproquest_cross%3E3065984523%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3065984523&rft_id=info:pmid/38844005&rfr_iscdi=true